A study published in the Journal of the National Comprehensive Cancer Network found that more than 80% of therapies tested in phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
